Loading...
•
Jun 30, 2024
AbCellera Q2 2024 Earnings Report
Announced financial results for the second quarter of 2024.
Key Takeaways
AbCellera reported a revenue of $7.3 million, with research fees contributing $5.5 million and milestone payments contributing $1.5 million. The company's net loss was $36.9 million, or $(0.13) per share.
ABCL635 and ABCL575 remain on track for anticipated Clinical Trial Applications (CTAs) in the second quarter of 2025.
Disclosed three T-cell engager programs under evaluation targeting PSMA, B7-H4, and CD-19.
The U.S. FDA cleared Abdera's Investigational New Drug (IND) application for ABD-147, and also granted it a Fast Track designation.
Reported the start of three additional partner-initiated programs with downstreams to reach a cumulative total of 93 partner-initiated program starts with downstreams.
AbCellera
AbCellera
AbCellera Revenue by Segment
Revenue by Segment
Research Fees Revenue
CapyFin.comLicensing Revenue
CapyFin.com Forward Guidance
The company aims to submit applications for clinical trials for ABCL635 and ABCL575 in the second quarter of 2025 and has focused preclinical work on its T-cell engager platform.
Revenue & Expenses
Visualization of income flow from segment revenue to net income